[HTML][HTML] Targeting and crossing the blood-brain barrier with extracellular vesicles
J Saint-Pol, F Gosselet, S Duban-Deweer, G Pottiez… - Cells, 2020 - mdpi.com
The blood–brain barrier (BBB) is one of the most complex and selective barriers in the
human organism. Its role is to protect the brain and preserve the homeostasis of the central …
human organism. Its role is to protect the brain and preserve the homeostasis of the central …
Crossing the blood-brain barrier with nanoparticles
The blood-brain barrier (BBB) is one of the most essential protection mechanisms in the
central nervous system (CNS). It selectively allows individual molecules such as small lipid …
central nervous system (CNS). It selectively allows individual molecules such as small lipid …
[HTML][HTML] Blood-brain barrier transport machineries and targeted therapy of brain diseases
An external file that holds a picture, illustration, etc. Object name is bi-6-225-g011. jpg
Introduction: Desired clinical outcome of pharmacotherapy of brain diseases largely …
Introduction: Desired clinical outcome of pharmacotherapy of brain diseases largely …
Nanotechnology-based strategies for siRNA brain delivery for disease therapy
Small interfering RNA (siRNA)-based gene silencing technology has demonstrated
significant potential for treating brain-associated diseases. However, effective and safe …
significant potential for treating brain-associated diseases. However, effective and safe …
Leveraging physiology for precision drug delivery
Physiological characteristics of diseases bring about both challenges and opportunities for
targeted drug delivery. Various drug delivery platforms have been devised ranging from …
targeted drug delivery. Various drug delivery platforms have been devised ranging from …
Nanoparticle‐mediated delivery of Anti‐PU. 1 siRNA via localized intracisternal administration reduces neuroinflammation
WT Ralvenius, JL Andresen, MM Huston… - Advanced …, 2024 - Wiley Online Library
Neuroinflammation is a hallmark of neurodegenerative disorders including Alzheimer's
disease (AD). Microglia, the brain's immune cells, express many of the AD‐risk loci identified …
disease (AD). Microglia, the brain's immune cells, express many of the AD‐risk loci identified …
New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease
Q Ouyang, Y Meng, W Zhou, J Tong… - Journal of Drug …, 2022 - Taylor & Francis
Alzheimer's disease (AD) is the most common neurodegenerative disease worldwide and its
incidence is increasing due to the ageing population. Currently, the main limitations of AD …
incidence is increasing due to the ageing population. Currently, the main limitations of AD …
Icariside II attenuates cerebral ischemia/reperfusion-induced blood–brain barrier dysfunction in rats via regulating the balance of MMP9/TIMP1
M Liu, W Wang, J Gao, F Li, J Shi, Q Gong - Acta Pharmacologica …, 2020 - nature.com
Cerebral ischemia/reperfusion (I/R) results in harmful consequences during ischemic stroke,
especially the disruption of the blood–brain barrier (BBB), which leads to severe …
especially the disruption of the blood–brain barrier (BBB), which leads to severe …
Tetramethylpyrazine attenuates blood-brain barrier disruption in ischemia/reperfusion injury through the JAK/STAT signaling pathway
P Gong, Z Zhang, Y Zou, QI Tian, S Han, Z Xu… - European Journal of …, 2019 - Elsevier
Tetramethylpyrazine (TMP) has been studied in depth and is widely used in the treatment of
many kinds of diseases in China. However, whether it has neuroprotective effects on …
many kinds of diseases in China. However, whether it has neuroprotective effects on …
Current status of non-viral gene therapy for CNS disorders
Introduction: Viral and non-viral vectors have been used as methods of delivery in gene
therapy for many CNS diseases. Currently, viral vectors such as adeno-associated viruses …
therapy for many CNS diseases. Currently, viral vectors such as adeno-associated viruses …